Results 111 to 120 of about 83,328 (323)
Journal for ImmunoTherapy of Cancer, 2019 Purpose To investigate the efficacy and safety of concurrent stereotactic radiosurgery (SRS) and ipilimumab or nivolumab in patients with untreated melanoma brain metastases.
Giuseppe Minniti +9 more
doaj +1 more source
A Case of Ipilimumab Induced Hypophysitis [PDF]
, 2015 Introduction Ipilimumab (Yervoy®) is a human monoclonal antibody that has been shown to significantly improve survival in cases of metastatic melanoma.1 Ipilimumab blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4), a protein receptor on the surface of T ...
Shiffrin, MD, Eric +1 more
core +2 more sources
International Journal of Cancer, EarlyView.What's New? Liver metastasis is an indicator of life expectancy for patients with advanced uveal melanoma (UM). Data on anticipated survival time following the diagnosis of liver metastasis, however, is lacking. The present study analyzed long‐term survival among UM patients who lived three or more years after liver metastases were diagnosed.
Jona Laukhuf +10 more
wiley +1 more source
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Case Reports in Oncology, 2018 Immune checkpoint inhibitors such as ipilimumab, a cytotoxic T-lymphocyte-associated antigen-4 inhibitor, have been widely used for advanced malignancies.
Yoshito Nishimura +6 more
doaj +1 more source
International Journal of Cancer, EarlyView.What's New? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel +21 more
wiley +1 more source
Local Delivery of CTLA-4 Blockade Inhibits Growth of Pancreatic Tumors [PDF]
, 2016 Immune checkpoint blockade has demonstrated great potential in activating antitumor immunity. Ipilimumab is a monoclonal antibody which targets cytotoxic T-lymphocyte antigen-4. CTLA-4 belongs to the CD28 class of receptors and is found on the surface of
Baltz, Jack
core +2 more sources
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1 [PDF]
, 2023 Martin Reck +26 more
openalex +1 more source
iNew Medicine, EarlyView.ABSTRACT Hepatocellular carcinoma (HCC) represents a significant global health issue, with the PD‐1/PD‐L1 axis serving a pivotal target for immunotherapy in this malignancy. However, a comprehensive bibliometric analysis of PD‐1/PD‐L1 research in HCC is lacking.
Xingyu Zhu +4 more
wiley +1 more source
Melanoma expression analysis with Big Data technologies [PDF]
, 2017 Melanoma is a highly immunogenic tumor. Therefore, in recent years physicians have incorporated drugs that alter the immune system into their therapeutic arsenal against this disease, revolutionizing in the treatment of patients in an advanced stage of ...
Aldana-Montes, Jose Francisco +4 more
core +2 more sources
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT This study evaluated the prognostic value of the C‐PLAN index in advanced esophageal squamous cell carcinoma (ESCC) patients receiving immune checkpoint inhibitor (ICI) therapy. A retrospective analysis of 241 eligible patients treated during February 2020 to January 2023 was conducted.
Yi Zhou +5 more
wiley +1 more source